SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kramer Robert

(Last)

(First)

(Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG

20879

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/14/2006

3. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO EBOL

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,065,043⁽¹⁾	I	By BioPharm, L.L.C.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	06/30/2004	06/30/2007	Class B Common Stock	467,528	$0.1	D
Employee Stock Option (right to buy)	⁽²⁾	05/25/2010	Class B Common Stock	43,588	$3.5	D
Employee Stock Option (right to buy)	⁽³⁾	05/25/2010	Class B Common Stock	71,495	$3.5	D

Explanation of Responses:

1. An entity named "RKRAMER, L.L.C." which is wholly owned by Mr. Kramer holds 21.01% (296,875 units) of the equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 4,065,043 shares of Common Stock. Mr. Kramer disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 854,139 shares.

2. The option is vested with respect to 17,435 shares of Class B Common Stock covered thereby and will vest with respect to the remaining shares as follows: 13,076 shares on December 31, 2006 and 13,077 shares on December 31, 2007.

3. The option is vested with respect to 28,598 shares of Class B Common Stock covered thereby and will vest with respect to the remaining shares as follows: 21,448 shares on December 31, 2006 and 21,449 shares on December 31, 2007.

Remarks:

Exhibit List: Exhibit 24-Power of Attorney

	/s/Daniel Abdun-Nabi, attorney in fact	11/14/2006
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.